Bionano Genomics (BNGO) Stock Overview
Provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BNGO Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$34.58 |
| 52 Week Low | US$2.68 |
| Beta | 2.06 |
| 1 Month Change | -4.66% |
| 3 Month Change | -9.67% |
| 1 Year Change | -89.47% |
| 3 Year Change | -99.78% |
| 5 Year Change | -99.19% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Jul 30
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
Apr 05Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Feb 11Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Dec 17Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Aug 29Shareholder Returns
| BNGO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.2% | 3.6% | -0.8% |
| 1Y | -89.5% | -19.7% | 15.8% |
Return vs Industry: BNGO underperformed the US Life Sciences industry which returned -20.8% over the past year.
Return vs Market: BNGO underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 5.5% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNGO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BNGO's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 99 | Robert Holmlin | bionano.com |
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules.
Bionano Genomics, Inc. Fundamentals Summary
| BNGO fundamental statistics | |
|---|---|
| Market cap | US$14.75m |
| Earnings (TTM) | -US$74.33m |
| Revenue (TTM) | US$27.43m |
Is BNGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNGO income statement (TTM) | |
|---|---|
| Revenue | US$27.43m |
| Cost of Revenue | US$26.04m |
| Gross Profit | US$1.39m |
| Other Expenses | US$75.72m |
| Earnings | -US$74.33m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.88 |
| Gross Margin | 5.06% |
| Net Profit Margin | -271.02% |
| Debt/Equity Ratio | 25.9% |
How did BNGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/19 03:43 |
| End of Day Share Price | 2025/08/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bionano Genomics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |